# EDGAR Filing Document

**Accession Number:** 0001995704
**File Stem:** 0001493152-26-028381
**Filing Date:** 2026-6
**Character Count:** 8644
**Document Hash:** a14e7c06150a16f3656fd4c9eca1be33
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-028381.hdr.sgml**: 20260612

**ACCESSION NUMBER**: 0001493152-26-028381

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20260612

**FILED AS OF DATE**: 20260612

**DATE AS OF CHANGE**: 20260612

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Cuprina Holdings (Cayman) LTD
- **CENTRAL INDEX KEY:** 0001995704
- **STANDARD INDUSTRIAL CLASSIFICATION:** ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42288
- **FILM NUMBER:** 261085044

**BUSINESS ADDRESS:**
- **STREET 1:** BLOCK 1090
- **STREET 2:** LOWER DELTA ROAD, #06-08
- **CITY:** SINGAPORE
- **STATE:** U0
- **ZIP:** 169201
- **BUSINESS PHONE:** (65) 8512 7275

**MAIL ADDRESS:**
- **STREET 1:** BLOCK 1090
- **STREET 2:** LOWER DELTA ROAD, #06-08
- **CITY:** SINGAPORE
- **STATE:** U0
- **ZIP:** 169201

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of June 2026**

Commission File Number: 001-42288

**Cuprina Holdings (Cayman) Limited**

**(Registrant's Name)**

**c/o Blk 1090 Lower Delta Road #06-08**

**Singapore 169201**

**(Address of principal executive office)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

**INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K**

**REGAIN COMPLIANCE WITH NASDAQ LISTING REQUIREMENT**

As previously disclosed, on November 26, 2025, Cuprina Holdings (Cayman) Limited (the "Company") received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company that the Company's non-compliance with Nasdaq Listing Rule 5550(a)(2), which requires primary securities listed on the Nasdaq Capital Market to maintain a minimum bid price of at least $1.00 per share (the "Minimum Bid Price Rule").

Pursuant to Nasdaq Listing Rule 5810(c)(3)(a), the Company has a compliance period of one hundred eighty (180) calendar days, or until May 26, 2026 (the "Compliance Period"), to regain compliance with the Minimum Bid Price Rule. The Company had failed to regain compliance with the Minimum Bid Price Rule within the Compliance Period. Consequently, the Company had filed a hearing request before the Nasdaq Hearings Panel (the "Panel") on May 28, 2026.

On June 11, 2026, the Company received a letter from the Hearings Advisor of Nasdaq, noting that the Nasdaq Listing Qualifications staff have advised the Hearings Department that the Company has regained compliance with the Minimum Bid Price Rule and that the Company is therefore in compliance with the Nasdaq Capital Market's listing requirements. Consequently, the hearing before the Panel scheduled to take place on July 7, 2026 has been cancelled. The Company's Class A Ordinary Shares will continue to be listed and traded on The Nasdaq Stock Market.

On June 12, 2026, the Company issued a press release announcing the letter from the Hearings Advisor of Nasdaq. The full text of the Press Release is attached as Exhibit 99.1 to this Current Report on Form 6-K.

**<u>Exhibits</u>**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | [Press release dated June 12, 2026](ex99-1.htm) |

---

**<u>SIGNATURES</u>**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
| **Cuprina Holdings (Cayman) Limited** | **Cuprina Holdings (Cayman) Limited** |
| By: | */s/ David Quek Yong Qi* |
| Name: | David Quek Yong Qi |
| Title: | Chief Executive Officer and Director |

---

Date: June 12, 2026

## Exhibit 99.1

**Exhibit 99.1**

 ****

**Cuprina Holdings (Cayman) Limited Regains Compliance with Nasdaq Listing Requirements**

**SINGAPORE, June 12, 2026 – Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR**) ("**Cuprina**" or "**the Company**"), a biomedical company developing and marketing products for the chronic wounds, infertility, medical waste recycling, and cosmeceuticals sectors, today announced that on June 11, 2026 it has regained compliance with the Nasdaq Capital Markets Listing Requirements.

As previously disclosed on May 29, 2026, the Company received a Staff Delisting Determinations Letter (the "Staff Determination") indicating that the Company's securities had closed below $1.00 per share for 30 consecutive business days, failing to meet the minimum bid price requirement under Listing Rule 5550(a)(2) (the "Minimum Bid Requirement"), and failed to regain compliance with the Minimum Bid Requirement within a period of 180 calendar days in accordance with Listing Rule 5810(c)(3)(a). At that time, the Company had appealed the Staff Determination by requesting a hearing before the Nasdaq Hearing Panel (the "Panel") pursuant to Listing Rule 5815.

The Company is pleased to announce that the Nasdaq Listing Qualifications staff have since advised the Hearings Department that the Company has regained compliance with the Minimum Bid Requirement and is now in full compliance with the Nasdaq Capital Market's listing requirement. As a result, the hearing before the Panel previously scheduled for July 7, 2026, has been cancelled. The Company's Class A Ordinary Shares will continue to be listed and traded on The Nasdaq Capital Market under the symbol "CUPR."

"We are gratified to regain compliance with Nasdaq," said CEO David Quek, "and look forward to continuing our initiatives to grow Cuprina's business in multiple biomedical sectors."

**About Cuprina Holdings (Cayman) Limited**

We are a Singapore-based biomedical and biotechnology company that is dedicated to the development and commercialization of innovative products for the management of chronic wounds, as well as operating in the infertility, medical waste recycling, and health and beauty sectors. Our expertise in biomedical research allows us to identify and utilize materials derived from natural sources to develop wound care products in the form of medical devices which meet international standards. For more information, please visit <u>https:// www.cuprina.com</u>.

**FORWARD-LOOKING STATEMENTS**

Certain statements contained in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the expected trading commencement and closing dates. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all, and other factors discussed in the "Risk Factors" section of the preliminary prospectus filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Any forward-looking statements contained in this press release speak only as of the date hereof, and Cuprina Holdings (Cayman) Limited specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

**Cuprina Holdings (Cayman) Limited Investor Contact**

Investor Relations

c/o Blk 1090 Lower Delta Road #06-08

Singapore 169201

+65 8512 7275

Email: <u>ir@cuprina.com.sg</u>

**Investor Relations Inquiries:**

Skyline Corporate Communications Group, LLC

Scott Powell, President

1177 Avenue of the Americas, 5<sup>th</sup> Floor

New York, New York 10036

Office: (646) 893-5835

Email: <u>ir@skylineccg.com</u>